Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data
Abiri, Arash , Nguyen, Theodore V. , Chen, Haidee , Krippaehne, Elise , Rahman, Arifeen S. , Roozdar, Pooya, Rosvall, Brandon R., Sabbaj, Michael , Adappa, Nithin D. , Chang, Eugene H., Chang, Michael T. , Kohanski, Michael A. , Hwang, Peter H. , Lee, Jivianne T. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Krippaehne, Elise , Rahman, Arifeen S , Beswick, Daniel , Chang, Michael T , Choby, Garret , Eide, Jacob G. , Douglas, Jennifer E , Hwang, Peter H , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Kuan, Edward C , Nguyen, Theodore V , Lerner, David K. , Workman, Alan D. , Wu, Shannon S. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H., Choby, Garret , Geltzeiler, Mathew , Le, Christopher H. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | January 15, 2025 | Volume: 15 | Issue: 6 | Pages: 585-593

10.1002/alr.23531 | PMID 39811891 Get It

ABSTRACTBackgroundOlfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of the anterior cranial fossa. Surgery can be performed with unilateral or bilateral resection depending on extent of involvement; however, there are currently no studies comparing outcomes between the two.MethodsProspective and retrospective data on primary ONB patients were collected from a multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts with similar baseline characteristics. Cox proportional hazards and Kaplan Meier analyses assessed overall survival (OS). Logistic regression assessed associations between extent of resection (unilateral versus bilateral) and tumor recurrence or postoperative cerebrospinal fluid (CSF) leak.ResultsA total of 187 ONB patients (47.6% female) with an average age of 53.6 ± 15.1 years were analyzed. Most tumors were unilateral (81.3%) and predominantly Kadish C (58.3%) or Hyams II (55.8%). Overall, 56.7% of patients underwent bilateral resection. Fifty‐four patients experienced tumor recurrence and nine had postoperative CSF leaks. Following PSM (n = 45/group), extent of resection was not associated with mortality (hazard ratio [HR] 1.73; p = 0.407) or OS (p = 0.400). There was no association between extent of resection and recurrence (odds ratio [OR] 0.90; p = 0.814) or postoperative CSF leak (OR 1.54; p = 0.647).ConclusionsFor ONB tumors where unilateral resection may be feasible and oncologically sound, the decision for unilateral versus bilateral resection showed no significant effect on survival, recurrence, or postoperative CSF leak. Oncologic outcomes may be comparable when resection is tailored to individual patient and tumor characteristics.
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Naing, Aung , Javle, Milind , Bajor, David L. , Shields, Anthony F. , Chawla, Sant P. , Safran, H., Powderly, John D. , D’Amato, Gina Z. , Meyer, Christian F. , Tang, Xiongwen , Yao, Sheng , Keegan, Patricia , Keegan, Patricia , Mahipal, Amit , Wang, Judy , Bauer, Todd Michael , Elias, Anthony , Davis, Elizabeth J.

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | January 14, 2025 | Volume: 8 | Issue: 1 | Pages: 71-81

10.36401/jipo-24-8 | PMID 39816916 Get It

Introduction This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti–programmed cell death-1 inhibitor) in patients with advanced malignancies. Methods Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B. The primary endpoint was safety assessment. Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) as assessed by the investigators according to Response Evaluation Criteria in Solid Tumors (version 1.1) and overall survival (OS). Results In part B, 166 patients, including the 42 patients with CCA, were enrolled and received toripalimab. Among the 166 patients, treatment-emergent adverse events (TEAEs) of any grade occurred in 158 (95.2%) patients, and 97 (58.4%) patients experienced TEAEs of Grade 3 or greater. The most common TEAE was fatigue (42.2%). Seven (4.2%) patients experienced TEAEs with a fatal outcome, none of which were identified by investigators as related to toripalimab. Investigator-assessed immune-related adverse events (irAE) of Grade 3 or higher occurred in 7 (4.2%) patients. In the CCA cohort, with the median follow-up of 4.4 months, the ORR and DCR were 4.8% (95% CI: 0.58, 16.16) and 40.5% (95% CI: 25.63, 56.72), respectively; median DoR was 7.8 (range 4.4+ to 7.8) months; median PFS was 2.1 (95% CI: 1.91, 3.88) months; median OS was not estimable. Conclusions Toripalimab had manageable side effects in patients with refractory cholangiocarcinoma and exhibited preliminary evidence of anti-tumor activity. However, further information regarding biomarkers is needed. ClinicalTrials.gov ID: NCT03474640
An X-linked long non-coding RNA, PTCHD1-AS, regulates autistic behaviors in humans and in mice
Scherer, Stephen W. , Bradley, Clarrisa A. , Ko, Sangyoon Y. , Ralph, Liam T. , D’Abate, Lia , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Tidball, Patrick , Fan, Xiaolian, Howe, Jennifer, Alexandrova, Roumiana, Pellecchia, Giovanna , Casallo, Guillermo, Paton, Tara , Wybenga-Groot, Leanne , Rijke, Jill de , Kadia, Ashish , Salazar, Nelson Bautista , Shum, Carole, Rennie, Olivia , Reuter, Miriam S. , Hoang, Ny , Sarikaya, Ege , Selvanayagam, Thanuja , Rutherford, Annabel, Rivero-Alfaro, Natalia, Marshall, Christian R. , Scala, Marcello , Runke, Cassandra , Kearney, Hutton M. , Francis, David, Plucinicazak, Jill, Iaboni, Alana, Sjaarda, Calvin , Jain, Anjali , Frey, Brendan J., Vorstman, Jacob , Frankland, Paul W. , Scherer, Stephen W , Scala, Marcello , Tian, Meng , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Mendes, Marla, Paton, Tara, Engchuan, Worrawat , Thiruvahindrapuram, Bhooma , Trost, Brett , Jin, Fuzi , Díaz-Mejía, J. Javier , MacDonald, Jeffrey R. , Deneault, Éric , Ross, P. Joel, Ellis, James , Georgiou, John , Amini, Aeen Ebrahim, Rivera-Alfaro, Natalia, Marshall, Christian R. , Christodoulou, John , Francis, David I. , Chung, Brian H Y, Pluciniczak, Jill, Wigby, Kristen M. , Nordahl, Christine Wu , Amaral, David Gil , Hudson, Melissa L., Guerin, Andrea, Elsabbagh, Mayada , Landa, Rebecca, Mital, Seema , Lesurf, Robert , Wilson, Michael D. , Ellegood, Jacob , Lerch, Jason P., Lee, Leo J. , Salter, Michael W. , Anagnostou, Evdokia, Collingridge, Graham L.

Mayo Clinic

No container title available | January 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619348/v1 Get It

Abstract There are ~100 genes or copy number variants (CNVs) used in genetic testing for Autism Spectrum Disorder (ASD, or autism). These genes are protein-coding, and the associated phenotypes often extend beyond socio-behavioral traits seen in autism including cognitive/medical complexities, epilepsy, and ADHD. Here, we characterize 27 males with ASD through whole genome sequencing (WGS), delineating X-chromosome microdeletions that implicate the long non-coding RNA (lncRNA) PTCHD1-AS as an ASD-susceptibility gene (OR=2.56, p=0.01). Two Ptchd1-as knockout (KO) murine models, created by removing the evolutionarily conserved exon-3, show ASD-like features in males, increasing repetitive behaviors and impairing typical social behavior and communication without overt cognitive comorbidities or ADHD-like behaviors. Hippocampus-dependent synaptic function, complex learning, and locomotor activity are unaffected in KO mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from post-natal day-7 onward in the dorsal striatum, a predominantly GABAergic brain region implicated in ASD. Multi-omics revealed transcriptomic alterations in striatal oligodendrocyte, astrocyte and neurons impacting myelination and plasticity pathways. Disrupting Ptchd1-as led to reductions in conventional Protein Kinase-C, altered Src and GSK3α/β phosphorylation, and an enhancement of synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit level dysregulation via Ptchd1-as in ASD etiology.
Patient-reported outcome trajectories the first 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Zeitouni, Daniel , Johnson, Sarah E. , Bisson, Erica F. , Mummaneni, Praveen V., Haid, Regis W., Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Meyer, Scott A., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Turner, Jay D. , Uribe, Juan S. , Tumialán, Luis M. , Coric, Domagoj , Bydon, Mohamad , Asher, Anthony L. , Ibrahim, Sufyan , Mummaneni, Praveen V. , Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 10, 2025 | Volume: 42 | Issue: 4 | Pages: 500-508

10.3171/2024.9.spine24351 | PMID 39793008 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations. METHODS This was a retrospective study of prospectively collected data using the Quality Outcomes Database. The primary outcomes of interest were achievement of the minimal clinically important difference (MCID) for the numeric rating scale for neck and arm pain, modified Japanese Orthopaedic Association, Neck Disability Index, and EQ-5D scores and postoperative satisfaction (North American Spine Society scale). Early and sustained improvement was defined as MCID achievement in at least one patient-reported outcome measure (PROM) at the 3-, 12-, and 24-month follow-ups. Transient improvement was defined as MCID achievement only at the 3-month and/or 12-month follow-up but not at the 24-month follow-up. Late improvement was defined as MCID achievement in at least one PROM only at the 24-month follow-up. RESULTS There were 630 patients included in the comparative analysis. A total of 463 (73.5%) patients achieved early and sustained improvement, 105 (16.7%) patients experienced transient improvement with subsequent decline, 25 (4.0%) patients reported late improvement, and 37 (5.9%) patients did not report any clinically meaningful improvement after surgery. Patients with an anterior approach were more likely to be in the early and sustained improvement group. African American patients (OR 2.98, 95% CI 1.14–7.76; p = 0.03) were more likely to report late improvement when compared with White patients. The overall satisfaction rate at the 24-month follow-up was 87.8%. CONCLUSIONS These findings indicate that 73.5% of patients achieve early and sustained improvement, and 87.8% of patients are satisfied with surgery 24 months postoperatively.
Plasma CycleGAN: Integrating Blood‐based Biomarkers for Cross‐modality Translation from MRI to PET
Chen, Yanxi , Weidman, David, Caselli, Richard J., Reiman, Eric M., Su, Yi , Fu, Yu Ping , Chen, Kewei , Caselli, Richard J. , Reiman, Eric M. , Wang, Yalin

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095616 Get It

AbstractBackgroundCross‐modality translation between MRI and PET presents significant challenges due to the distinct mechanisms underlying those modalities. Currently, the leading method for this translation is CycleGAN. Previous studies have proved a strong correlation between BBBMs and brain amyloid status measured by PET. However, the impact of blood‐based biomarkers (BBBMs) on PET image synthesis has not yet been thoroughly evaluated. In this study, we propose Plasma CycleGAN, a generative model based on CycleGAN to synthesize PET images from MRI, while also incorporating BBBMs and other clinical covariates. We show that Plasma CycleGAN outperforms the state‐of‐the‐art CycleGAN for MRI‐to‐PET translation. Our method is the first to integrate BBBMs in a conditional cross modality translation from MRI to PET.MethodOur model was built on CycleGAN architecture, while the backbone was improved by integrating BBBMs as additional conditions in the input domain. To be specific, we introduce a masked perturbation in the MRI image, whose voxel‐level magnitudes are learnable parameters in the neural network. The dataset we used to evaluate our model is downloaded from the ADNI database. The cohort contains 160 subjects with matching BBBM, T1‐weighted MRI images, amyloid PET, and clinical features, including age, sex, weights, etc. The synthesized PET images are compared with the ground truth PET images for performance evaluation using traditional metrics like structural similarity index (SSIM), peak‐signal‐to‐noise ratio (PSNR) and mean square error (MSE). In addition, the Pearson correlation coefficients (PCCs) of the masked SUVR ratios were calculated.ResultWe evaluated the baseline CycleGAN model using MRI input, as well as combined inputs of MRI+BBBM and other clinical features. Our model achieved an SSIM of 0.72±0.16 and PSNR of 22.8±2.3 in PET image synthesis task using MRI+ Aβ42/40, both yielding the best results among all input combinations. MRI+sex achieved the best result using MSE measurement. PCCs of all experimental results ranged from 0.44 to 0.5.ConclusionWe introduce Plasma CycleGAN, the first generative model to integrate BBBMs and clinical features in PET image synthesis from MRI images. In PET image synthesis task, our proposed integrated model outperforms the baseline CycleGAN model.
MRI and PET findings with long‐term gantenerumab treatment: results from the DIAN‐TU trial
Hornbeck, Russ C. , Li, Yan , Clifford, David B., Santacruz, Anna , Wang, Guoqiao , Klein, Gregory , Baudler, Monika, Doody, Rachelle S., Kerchner, Geoffrey A. , Team, The DIAN‐TU Study, Benzinger, Tammie L.S. , Gordon, Brian A. , McCullough, Austin , Flores, Shaney , Koeppe, Robert A. , Jack, Clifford R. , McDade, Eric , Llibre‐Guerra, Jorge J. , Mills, Susan, Supnet, Charlene , Ibanez, Laura , Atri, Alireza , Bateman, Randall J. , Team, The DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.094832 Get It

AbstractBackgroundAnti‐amyloid monoclonal antibody therapies for AD have documented plaque removal on amyloid PET scans. We evaluate the findings for amyloid PET, tau PET, FDG PET and volumetric MRI over the course the open label extension (OLE) for the DIAN‐TU gantenerumab treatment, compared to the last imaging obtained prior to the OLE (to evaluate for potential rebound effects) and in comparison to longitudinal imaging in the DIAN Observational study.MethodThis double‐blind, phase 2/3 trial (2012‐2019), followed by open‐label extension (OLE), investigated varying gantenerumab doses up to 1500 mg SQ q2 weeks [NCT NCT01760005]. We report long‐term amyloid‐plaque removal by PET and findings for metabolic FDG PET and tau PET, and additionally changes of atrophy on volumetric MRI. Imaging measures were secondary outcome analyses. Comparison is made between the treatment cohort and controls (DB placebo participants who didn’t enter OLE, plus external controls from the DIAN OBS). Estimated years to onset was included as a covariate. The gap period of ∼1 year is specifically analyzed to estimate any “rebound” effect on amyloid or tau accumulation or neurodegeneration. Volumetric MRI measures include hippocampal volumes, lateral ventricular volumes, and white matter hyperintensities.ResultIn participants who were asymptomatic at baseline and treated with gantenerumab (n = 53), amyloid‐plaque removal measured by PIB‐PET in Centiloids was dose‐dependent. Few participants had reached completely negative levels (below 24). No statistical significance was found for FDG PET, tau PET, or volumetric MRI, including hippocampal volumes. Impact of the gap period of ∼1 year (gap in treatment) on the rate of amyloid accumulation compared to the rate of accumulation predicted in observational studies of this cohort is under evaluation, as are the other imaging measures.ConclusionWhile no overall effect was observed in the total group for non‐amyloid measures, results suggest dose dependent clearance of amyloid plaque in asymptomatic DIAD mutation carriers following long‐term, high‐dose gantenerumab. The potential “rebound effect” of elevated amyloid accumulation for participants for whom there was a significant gap in therapy between the trial and the OLE is under evaluation and will be presented, as will the variables for FDG PET, tau PET, and volumetric MRI.
CSF biomarkers of immune activation and Alzheimer’s disease for predicting cognitive impairment risk in the elderly
White, Launia J. , Hendrix, Rachel , Ulrich, Jason D. , Henson, Rachel L. , Knight, William C. , Martens, Yuka A. , Wang, Ni , Starling, Skylar C , Ren, Yingxue , Asmann, Yan W. , Syrjanen, Jeremy A. , Vassilaki, Maria , Petersen, Ronald C. , Kanekiyo, Takahisa , Shue, Francis , Roy, Bhaskar, Xiong, Chengjie , Mielke, Michelle M. , Cruchaga, Carlos , Holtzman, David M. , Bu, Guojun , Heckman, Michael G.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.087693 Get It

AbstractBackgroundThe immune system is substantially involved in the development and progression of age‐related cognitive decline and Alzheimer’s disease (AD).MethodAs genetic and environmental factors interactively impact these conditions, we investigated how risk factors such as APOE genotype, age, and sex influence immune activation markers and AD biomarkers in cerebrospinal fluid (CSF) in elderly individuals enrolled in the Mayo Clinic Study of Aging cohort. Among cognitively unimpaired individuals aged over 65 at the baseline visit (N=298), we measured 365 CSF immune activation markers using the proximity extension assay.ResultWe found that age, sex, and diabetes status are associated with altered CSF levels of immune activation markers independently of other factors. For CSF AD biomarkers, we observed significant positive correlations between age and total tau, phosphorylated tau‐181 (p‐tau181), neurofilament light (NfL), and YKL40. APOE4 was also associated with lower Aβ42 and higher SNAP25 in CSF. We further examined whether baseline visit variables can predict cognitive decline, represented by the conversion from CDR=0 to CDR>0. We found that age, Aβ42, NfL, and REG4 were independently correlated with CDR conversion risk. When the cohort was dichotomized by their median values, older participants with lower Aβ42, higher NfL, and higher REG4 at baseline developed cognitive impairment during the follow up with a c‐index of 0.762 while age alone had a c‐index of 0.699.ConclusionTogether, our results suggest that assessing CSF immune activation markers and AD biomarkers can improve the prediction of cognitive impairment risk in the elderly.
Comparison of tau‐PET tracers for in vivo Braak staging: the HEAD Study
Macedo, Arthur C. , Rahmouni, Nesrine , Servaes, Stijn , Wang, Yi‐Ting , Socualaya, Kely Monica Quispialaya, Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Therriault, Joseph , Servaes, Stijn , Tissot, Cécile , Lussier, Firoza Zubeida , Arias, Jaime Fernández , Hosseini, Seyyed Ali , Ferreira, Pâmela C.L. , Bellaver, Bruna , Ferrari‐Souza, João Pedro , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Pascual, Belén , Gordon, Brian A. , Pascoal, Tharick Ali , Rosa-Neto, Pedro

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.087615 Get It

AbstractBackgroundTau‐PET tracers allow for in vivo Braak staging of individuals in the Alzheimer’s disease (AD) continuum. The impact of tracers’ characteristics for Braak staging using tau‐PET remains unclear. Therefore, we performed a head‐to‐head comparison of Braak staging using first‐ and second‐generation tau‐PET tracers.MethodWe assessed 51 cognitively unimpaired (CU) and 49 cognitively impaired participants (mean [SD] age 69.4 [7.5] years) with at least two tau‐PET ligands ([18F]MK6240, [18F]AV1451, and/or [18F]RO948) at McGill University, as part of the HEAD study. We calculated standardized uptake value ratios (SUVR) in Braak‐like regions of interest (ROI) for each ligand and investigated their association using Spearman’s correlation. Thresholds defined the presence of tauopathy in each Braak ROI, which was used to assign a Braak stage to each participant. Finally, we assessed the agreement between the Braak staging provided by each tracer, both for the traditional (using separate Braak stages – 0, I, II, III, IV, V, and VI) and simplified (using joint Braak stages – 0, I‐II, III‐IV, and V‐VI) frameworks.ResultIn all Braak ROIs, we found positive correlations between the SUVR values of the three tracers (Figure 1). The strongest correlation was between [18F]MK6240 and [18F]RO948 in Braak II (r=0.94), and the weakest between [18F]AV1451 and [18F]RO948 in VI (r=0.51). Inter‐tracer agreement regarding the latest stage of abnormality was substantial or nearly perfect between pairs of tracers but moderate between the three tracers (Figure 2A). The simplified framework presented greater agreement compared to traditional Braak staging, except between [18F]MK6240 and [18F]RO948. At the ROI level, the lowest agreements were observed for Braak II and I‐II, when [18F]MK6240 and [18F]RO948 were compared to [18F]AV1451 (Figure 2B‐C). [18F]AV1451 had the highest probability of overestimating the Braak stage assigned by [18F]MK6240 and by [18F]RO948, especially at earlier stages (Figure 3).ConclusionThe ligands presented moderate to nearly perfect agreement for in vivo staging of AD severity. Off‐target binding of [18F]AV1451 to the choroid plexus might explain disagreements at early stages. Overall, slight improvements in agreements were achieved with the simplified framework, as observed in histopathological staging.
Proteomic Analysis Resolves Distinct Molecular Signatures in Alzheimer’s Disease Brain Across Diverse Racial Groups
Fox, Edward J., Liu, Yue , Modeste, Erica , Duong, Duc M. , Yin, Luming, Gearing, Marla , Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Scanlan, Jo, Linden, Abby Vander , Poehlman, William L. , Chen, Xianfeng , Baheti, Saurabh , Ho, Charlotte C.G. , Nguyen, Thuy , Yepez‐Sisalema, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Carrasquillo, Minerva M. , Beach, Thomas G., Golde, Todd E. , Haroutunian, Vahram, Zhang, Bin , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Seyfried, Nicholas T. , Disease, Accelerating Medicine Partnership for Alzheimer’s (AMP‐AD) Diversity Initiative, Seifar, Fatemeh , Shantaraman, Anantharaman , Lah, James J. , Heath, Laura , Wang, Erming , Wang, Minghui , Wang, Xue , Carrasquillo, Minerva M. , Runnels, Alexi , Beach, Thomas G. , Barnes, Lisa L. , Haroutunian, Vahram , Soni, Rajesh K , Greenwood, Anna, Levey, Allan I. , Wingo, Aliza P. , Wingo, Thomas S , Disease, Accelerating Medicine Partnership for Alzheimer’s (AMP‐AD) Diversity Initiative

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092542 Get It

AbstractBackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within the non‐Hispanic White (NHW) population. To address this, Accelerating Medicines Partnership in AD (AMP‐AD) aimed to promote inclusivity in multi‐omics AD research, to unravel unique molecular signatures and pathways. The study aimed to provide comprehensive insights into the proteomic landscape of AD across diverse racial groups.MethodDorsolateral prefrontal cortex (DLPFC) and superior temporal gyrus (STG) brain tissues were donated from multiple centers (Mayo Clinic, Emory University, Rush University, Mt. Sinai School of Medicine) and were harmonized through neuropathological evaluation, specifically adhering to the Braak staging and CERAD criteria. Among 1105 DLPFC tissue samples (980 unique individuals), 322 were from African American donors, 214 from Latino Americans, 551 from NHW donors, and the rest were from a mixed or unknown racial background. Among 280 STG samples, 86 were African American, 76 Latino American, 116 NHW and the rest were mixed or unknown ethnicity. All tissues were uniformly homogenized and analyzed by tandem mass tag‐based mass spectrometry (TMT‐MS). Following quality control (QC), proteins with more than 50% missing values were removed and iterative principal component analysis was conducted to remove outliers within brain regions. Differential protein expression was conducted within and across races after adjusting for batch using regression‐analysis.ResultIn total, 9,180 proteins from the DLPFC, and 9,734 proteins from STG brain tissues were quantified by TMT‐MS. Further analysis identified approximately 3,000 differentially abundant proteins in AD brains compared to controls within race. The AD‐associated differentially abundant proteins were strongly correlated between DLPFC and STG regions and with CERAD and Braak. Protein levels of MAPT and APP demonstrated equivalent disease‐related elevations in both African American and NHW individuals with AD. Notably, after adjusting for AD, significant differences in protein levels were identified across race.ConclusionThe proteomics approach employed by AMP‐AD sheds light on the brain proteome in AD across diverse racial groups, emphasizing the importance of inclusive research in establishing robust and generalizable discoveries. The identified proteins here could underscore racial disparities beyond disease association, contributing to a more nuanced understanding of AD pathophysiology.